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Abstract
Background: In clinical research of rare diseases, where small patient numbers and disease heterogeneity limit
study design options, registries are a valuable resource for demographic and outcome information. However, in
contrast to prospective, randomized clinical trials, the observational design of registries is prone to introduce
selection bias and negatively impact the validity of data analyses.
The objective of the study was to demonstrate the utility of case-control matching and the risk-set method in
order to control bias in data from a rare disease registry. Data from the International Collaborative Gaucher Group
(ICGG) Gaucher Registry were used as an example.
Methods: A case-control matching analysis using the risk-set method was conducted to identify two groups of
patients with type 1 Gaucher disease in the ICGG Gaucher Registry: patients with avascular osteonecrosis (AVN) and
those without AVN. The frequency distributions of gender, decade of birth, treatment status, and splenectomy
status were presented for cases and controls before and after matching. Odds ratios (and 95% confidence intervals)
were calculated for each variable before and after matching.
Results: The application of case-control matching methodology results in cohorts of cases (i.e., patients with AVN)
and controls (i.e., patients without AVN) who have comparable distributions for four common parameters used in
subject selection: gender, year of birth (age), treatment status, and splenectomy status. Matching resulted in odds
ratios of approximately 1.00, indicating no bias.
Conclusions: We demonstrated bias in case-control selection in subjects from a prototype rare disease registry and
used case-control matching to minimize this bias. Therefore, this approach appears useful to study cohorts of
heterogeneous patients in rare disease registries.
Background
Rare diseases, exemplified by Gaucher disease, are
defined as having a prevalence of fewer than 200,000
patients [1]. A major impediment to the study of these
diseases is the scarcity of patients in any one city or
country. Nevertheless, the global burden of patients
affected by rare diseases is substantial: at least 30 million
patients are estimated to suffer from one of the 7,000
rare diseases currently identified [2]. On average, each
rare disease is estimated to afflict 4,200 patients [2]. Our
search of the word ‘registry’ on clinicaltrials.gov as of 4
May 2011 identified 913 results.
Rare disease patient registries provide relatively large
representative cohorts for clinical study. As a rule indivi-
dual rare diseases are highly heterogeneous in phenoty-
pic expression, which hinders optimal natural history or
outcomes studies using data from rare disease registries.
An excellent example of a rare disease registry is the
International Collaborative Gaucher Group (ICGG)
Gaucher Registry, which has been collecting patient data
for 20 years. In fact, the ICGG Gaucher Registry is the
prototype by which several disease registries have been
created (Table 1).
Randomized double-blind, placebo controlled clinical
trials represent the highest category of evidence base for
determining efficacy of treatments. For rare hereditary
diseases, such as Gaucher disease, there are significant
impediments to the design and conduct of adequately
powered clinical trials. For example, rarity of the disease
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hinders the development of appropriate subject groups
for study that are controlled for factors such as age, sex,
disease severity, and genotype. Moreover, following the
introduction of an effective therapy, few patients remain
treatment-naive for evaluation of alternative therapies,
which may differ in mechanism of action and have over-
lapping effects. An additional consideration when evalu-
ating long-term treatment outcomes is the chronic
nature of many rare diseases, which often extends beyond
the reasonable time span of a traditional clinical trial. As
an alternative model, the Framingham heart study pro-
vides an example of the design and conduct of an obser-
vational cohort study designed to collect longitudinal
data with the goal of studying health outcomes [3].
An important feature of disease registries is the poten-
tial to provide real-world data from the community [2].
Therefore, data from registries could complement data
obtained from clinical trials to develop optimal stan-
dards of care for rare diseases. Indeed, data from the
ICGG Gaucher Registry have been effectively used to
demonstrate treatment outcomes in multiple disease
compartments which have been used to develop a stan-
dard of care and expected treatment outcomes for Gau-
cher disease [4-6]. These have formed the basis for
developing therapeutic goals [7] and to define endpoints
for subsequent clinical trials of new therapeutic agents
[8-10]. Analytical approaches used in these studies from
the ICGG Gaucher Registry have included multivariate
mixed-effects analyses [11], propensity scoring and non-
linear effects modeling [12], and Poisson regression
modeling to determine relative risk [13].
A major confounder with registry data is selection
bias, which is inherent in the observational design of the
registry and the flexibility accorded to contributors to
determine which patients to include and what data to
submit [14]. An approach to overcome such selection
bias is the use of case-control matching, in which cases
are selected based on the presence of a specific disease
outcome and matched to controls that are identified to
not have that outcome. These cases and controls are
matched according to values for a set of background
characteristics. However, this type of analysis requires a
population sufficiently large to identify cases of interest
and randomly selected controls. With almost 6,000
enrolled subjects, the ICGG Gaucher Registry is the lar-
gest worldwide registry for an inborn error of metabo-
lism, and it becomes feasible to attempt case-control
matching.
In this paper, the cases of interest are patients with
skeletal avascular osteonecrosis (AVN), a serious and
irreversible complication of Gaucher disease that occurs
sporadically and unpredictably in a subset of patients.
The set of matched controls are patients with type 1
Gaucher disease who did not develop AVN. By applying
the risk-set method approach, we demonstrate the utility
of the case-control matching method to identify case
and control patients who have comparable distributions
for four common parameters used in subject selection:
gender, year of birth (age), treatment status, and sple-
nectomy status. We conclude that selection bias in case-
control selection of subjects from rare disease registries
occurs and that this can be overcome through case-con-
trol matching to minimize bias. Therefore, application
Table 1 Rare Disease Registries[29]
Lysosomal Storage Diseases with Registries Examples of Rare Diseases with Registries
￿ Fabry disease ￿ Adrenocortical Tumors
￿ Gaucher disease ￿ Alport Syndrome
￿ Hunter syndrome ￿ Epidermolysis Bullosa
￿ Mucopolysacchiridosis (MPS) type 1 ￿ Inflammatory Breast Cancer
￿ Pompe disease ￿ Juvenile Rheumatoid Arthritis
￿ Neuroendocrine Tumors
￿ Neurological Autoimmune Disease
￿ Neutropenia
￿ Primary Ciliary Dyskines
￿ Primary & Secondary Immunodeficiency
￿ Smith Magenis Syndrome
￿ Thrombotic Thrombocytopenia Purpura
￿ Unexplained Cardiac Arrest
￿ Vascular Anomalies Associated with Coagulapathy
￿ Wilms Tumor Suppressor Gene Mutation (WT1) Associated Diseases
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comes or natural history within rare disease registries.
Methods
International Collaborative Gaucher Group (ICGG)
Gaucher Registry
The ICGG Gaucher Registry was started to track the
clinical, demographic, genetic, biochemical and thera-
peutic characteristics of patients with Gaucher disease
throughout the world, irrespective of disease severity,
treatment status, or treatment choice [15]. An indepen-
dent international group of physician experts in Gaucher
disease provides scientific direction and governance of
the Registry, with logistical support from Genzyme, a
Sanofi Company (Cambridge, Massachusetts). Since its
inception in 1991, with Institutional Review Board/
Ethics Committee approvals, over 700 physicians from
more than 60 countries have voluntarily submitted de-
identified data on over 5,800 patients to the Registry.
Study population
We identified all patients in the ICGG Gaucher Registry
as of 1 October 2010, with type 1 Gaucher disease and
reported treatment status including date of initiation of
imiglucerase (Cerezyme
®,G e n z y m eC o r p o r a t i o n )o r
alglucerase (Ceredase
®, Genzyme Corporation) treat-
ment. Until early 2010, alglucerase and imiglucerase
w e r et h eo n l yc o m m e r c i a l l ya p p r o v e de n z y m et r e a t -
ments for Gaucher disease. Alglucerase and imiglucerase
have been shown to be therapeutically equivalent in a
randomized, two-arm clinical trial [16]. For simplicity,
these two treatments will be denoted as imiglucerase in
this publication.
Case identification
Based on data from the ICGG Gaucher Registry skeletal
case report forms, we identified all patients with affirma-
tive reports of AVN. Cases of AVN were typically ascer-
tained through radiographic or magnetic resonance
image (MRI) results. An affirmative report was based on
the treating physician’s review of the corresponding
radiographic or MRI result. Each patient’s earliest date
of an affirmative report of AVN was considered to be
the index date.
Case-control matching
In order to quantify the association between risk factors
with the onset of AVN, we initially sought to identify all
patients without AVN as controls in our analysis. Follow-
ing a review of characteristics between cases and con-
trols, apparent differences between the groups according
to gender, decade of birth, imiglucerase/alglucerase treat-
ment status, and history of splenectomy were noted.
Prior to the advent of imiglucerase, patients underwent
splenectomy for relief of cytopenia and/or pressure
symptoms; however, splenectomy itself has the potential
to alter the phenotype and natural course of the disease
[17,18]. Since these variables (gender, decade of birth,
treatment status, history of splenectomy) may impact
both the risk of AVN and also may be associated with
other risk factors for AVN, we implemented a case-con-
trol matching algorithm using the risk-set method [19].
For each case of AVN, we identified all controls who
matched on gender and year of birth (± five years).
Among these matched controls, we then assigned their
index date to be the same date as the AVN onset date for
the corresponding case and excluded controls who were
not followed-up in the ICGG Gaucher Registry as of that
index date. We further determined whether the case and
controls as of their index date had 1) initiated treatment
with imiglucerase/alglucerase and 2) underwent prior
splenectomy. For each individual case, we randomly
selected up to five controls who matched on all four
characteristics [20].
Statistical analysis
We presented the frequency distributions of gender,
decade of birth, treatment status, and splenectomy sta-
tus for cases and controls before and after matching.
We calculated odds ratios (and 95% confidence inter-
vals) for each variable before and after matching and
present the percent bias for each variable [21,22] using
the formula below:
[(ARR − RR/RR)] × 100
where
ARR = Apparent exposure relative risk (i.e., before
matching)
RR = ‘True’ o rf u l l ya d j u s t e de x p o s u r er e l a t i v er i s k( i .
e., after matching)
An odds ratio of 1·00 indicates no difference in the
distributions between cases and controls [23]. All ana-
lyses were conducted in SAS 9·1 (SAS Institute Inc.,
Cary, North Carolina, USA) in accordance with
STrengthening the Reporting of OBservational studies
in Epidemiology (STROBE) guidelines [24].
Results
As of 1 October 2010, the ICGG Gaucher Registry con-
tained a total of 5,894 patients. Of these, 5,156 patients
met the study inclusion criteria: type 1 Gaucher disease,
known treatment status, and known date of initiation of
treatment. From this group of patients (n = 5,156), 176
patients had a history of AVN with no accompanying
assessment or diagnosis dates reported to the Registry
and were therefore excluded from the study. Of the
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reports of AVN and 4,127 patients without AVN.
Patient characteristics before matching are shown in
Table 2. Before matching, the ratio of females to males
was similar in both groups, with a slightly higher per-
centage of females in the control group. In contrast,
before matching, a higher percentage of patients born in
earlier decades (i.e. older patients with more years at
risk) reported AVN compared to the group without
AVN. Additionally, distributions of splenectomy and
treatment status were substantially different between
case and control patients, as indicated by odds ratios of
3·21 for splenectomy status and 6·09 for treatment
status.
In general, matching resulted in odds ratios of
approximately 1·00 as seen in Table 3. After matching,
the distributions of patients born in each decade in both
groups were more comparable. For splenectomy status
and treatment status, where differences in distributions
before matching were apparent, the percent bias was
((3·21 - 1·32)/1·32) × 100 = 143·2% and ((6·09 - 1·10)/
1·10) × 100 = 453·6%, respectively (Figure 1).
Discussion
Registries for the study of rare diseases serve to create
pooled patient populations that are sufficiently large for
robust statistical analysis. However, studies based on
registry databases are vulnerable to bias. For example,
domains captured in the database may differ from cen-
ter to center; patients with less severe disease may not
be enrolled or, if enrolled, may have fewer data col-
lected. In addition, the data may be incomplete. Verifi-
cation of the quality or completeness of the data may be
lacking and there is no systematic evaluation of statisti-
cal methods to generate an unbiased dataset from regis-
try data. Nevertheless, as many long-term studies
[25-27] have demonstrated in a variety of diseases, hav-
ing longitudinal data is critical to understanding the nat-
ural history or response to treatment of a chronic
disease. This type of data is often analyzed using case-
control methodology.
However, case-control studies in patients with rare
diseases, whether performed in individual large clinics
or through disease registries, are inherently vulnerable
to bias. Chronic diseases, such as Gaucher disease, are
highly heterogeneous, and the phenotype can vary
depending on the age of onset, age of the patient,
adjunct therapies, genotype, access to health-care
resources, and environmental factors. Patients with
milder disease tend to have less contact with specialty
clinics and less frequent and intensive follow-up; many
are not diagnosed for several years [28]. When more
Table 2 Patient Characteristics Before Matching
Patients with Avascular Necrosis Patients without Avascular Necrosis Odds Ratio 95% Confidence Interval
Before Matching 853 4127
Gender, n (%)
Male 423 (49·6) 1899 (46·0) Reference*
Female 430 (50·4) 2228 (54·0) 0·89 (0·78, 1·02)
Year of Birth, n (%)
1910 - < 1920 4 (0·5) 34 (0·8) 0·49 (0·18, 1·31)
1920 - < 1930 21 (2·5) 125 (3·0) 0·66 (0·42, 1·05)
1930 - < 1940 75 (8·8) 198 (4·8) 1·27 (0·96, 1·68)
1940 - < 1950 114 (13·4) 384 (9·3) 1·06 (0·83, 1·35)
1950 - < 1960 146 (17·1) 529 (12·8) Reference*
1960 - < 1970 147 (17·2) 590 (14·3) 0·92 (0·73, 1·16)
1970 - < 1980 156 (18·3) 665 (16·1) 0·88 (0·70, 1·10)
1980 - < 1990 129 (15·1) 659 (16·0) 0·76 (0·60, 0·96)
1990 - < 2000 58 (6·8) 633 (15·3) 0·39 (0·29, 0·53)
2000 - < 2010 3 (0·4) 310 (7·5) 0·04 (0·01, 0·14)
Treatment Status, n (%)
Untreated 35 (4·1) 995 (24·1) Reference*
Treated 818 (95·9) 3132 (75·9) 6·09 (4·34, 8·55)
Splenectomy Status, n (%)
Spleen Intact 438 (51·3) 3407 (82·6) Reference*
Splenectomized 415 (48·7) 720 (17·4) 3·21 (2·81, 3·67)
* “Reference” indicates group used for odds ratios comparison.
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there has been no validation to our knowledge, whether
non-random selection of a control, pooling all controls,
or selecting a group of controls are valid methods to
reduce selection bias. Therefore, selecting an unbiased
control group is not simply a matter of finding subjects
who are negative for the disease variable being studied,
and arbitrary selection of controls or pooling of controls
does not obviate having a biased control group that may
lead to an erroneous conclusion. The method we used
permitted appropriate risk-set selection and subsequent
matching, and it circumvented the challenge of clinical
heterogeneity in observational registries. However, it is
applicable only in the context of a large, well annotated
patient cohort combined with extensive follow-up data.
This study shows that some biases can be successfully
minimized in an observational database such as the
ICCG Registry by using case-control matching and a
modified risk-set method approach. Applying this estab-
lished method to registry data, we demonstrated the
effective use of the case-control matching method to
yield cohorts of case and control patients who have
comparable distributions for four common areas used in
subject selection: gender, year of birth (age), treatment
status, and splenectomy status. The results after match-
ing showed odds ratios close to one, which indicates no
difference or bias between cases and controls on these
matching variables. Skeletal avascular osteonecrosis was
selected for this analysis because it is a complication of
type 1 Gaucher disease associated with serious acute
and chronic morbidity[13], but it is a difficult target to
study because it occurs sporadically and unpredictably.
The matched patients now co n s t i t u t ear e s o u r c ef o r
Table 3 Patient Characteristics After Matching
Patients with Avascular Necrosis Patients without Avascular Necrosis Odds Ratio 95% Confidence Interval
After Matching 672 2390
Gender, n (%)
Male 323 (48·1) 1139 (47·7) Reference*
Female 349 (51·9) 1251 (52·3) 0·99 (0·85,1·15)
Year of Birth, n (%)
1910 - < 1920 3 (0·4) 17 (0·7) 0·66 (0·21,2·07)
1920 - < 1930 17 (2·5) 78 (3·3) 0·79 (0·47,1·31)
1930 - < 1940 64 (9·5) 163 (6·8) 1·24 (0·91,1·68)
1940 - < 1950 88 (13·1) 299 (12·5) 1·00 (0·76,1·32)
1950 - < 1960 114 (17·0) 387 (16·2) Reference*
1960 - < 1970 89 (13·2) 379 (15·9) 0·84 (0·63,1·10)
1970 - < 1980 124 (18·5) 404 (16·9) 1·03 (0·80,1·33)
1980 - < 1990 115 (17·1) 354 (14·8) 1·08 (0·83,1·40)
1990 - < 2000 55 (8·2) 276 (11·5) 0·73 (0·53,1·01)
2000 - < 2010 3 (0·4) 33 (1·4) 0·37 (0·12,1·15)
Treatment Status, n (%)
Untreated 322 (47·9) 1197 (50·1) Reference*
Treated 350 (52·1) 1193 (49·9) 1·07 (0·92,1·24)
Splenectomy Status, n (%)
Spleen intact 447 (66·5) 1752 (73·3) Reference*
Splenectomized 225 (33·5) 638 (26·7) 1·28 (1·09,1·51)
* “Reference” indicates group used for odds ratios comparison.
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Figure 1 Odds Ratios in Subjects With and Without Avascular
Osteonecrosis Before and After Matching.
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now be studied without introducing bias due to differ-
ences in age, gender, treatment status, and splenectomy
status.
In this study, the main outcome variable was the
change in odds ratios. The odds ratios indicate the
amount of bias in the groups. The largest changes were
observed for treatment status and splenectomy status.
This difference may be due to several factors. One factor
is that many of the controls, even though they were not
symptomatic for the variable in question, were receiving
imiglucerase therapy. Because biased selection of con-
trols may over or under represent the variables in case-
control pairs, having more controls than cases may have
made it appear as if AVN was more likely to occur in
younger patients or subjects without a history of imiglu-
cerase therapy or who underwent a prior splenectomy.
Having randomly matched controls, the cases and con-
trols were numerically equally represented, thus redu-
cing the bias. The purpose of having matched data is to
reduce the finding of any such relationship due to
biased case or control selection.
The practical application of this technique is to vali-
date that case-control studies have a minimized bias in
subject selection, which provides researchers with an
analytical tool to test their hypotheses of interest. This
study has demonstrated the use of case-control match-
ing to reduce the bias between groups. We conclude
that bias in case-control selection in subjects from rare
disease registries can occur, and case-control matching
is one method to minimize this bias.
Conclusions
This study shows that some biases can be successfully
minimized in an observational database such as the
ICCG Gaucher Registry by using case-control matching
and a modified risk-set method approach.
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